Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Nov 12 04:00PM ET
47.84
Dollar change
-2.89
Percentage change
-5.70
%
Index- P/E- EPS (ttm)-6.46 Insider Own6.46% Shs Outstand92.34M Perf Week-8.32%
Market Cap4.42B Forward P/E- EPS next Y-5.11 Insider Trans-0.99% Shs Float86.37M Perf Month-14.86%
Income-558.99M PEG- EPS next Q-1.35 Inst Own96.58% Short Float3.68% Perf Quarter-7.57%
Sales522.75M P/S8.45 EPS this Y24.07% Inst Trans11.13% Short Ratio4.50 Perf Half Y16.77%
Book/sh3.76 P/B12.72 EPS next Y18.49% ROA-40.27% Short Interest3.18M Perf Year37.12%
Cash/sh6.80 P/C7.04 EPS next 5Y37.90% ROE-295.34% 52W Range34.06 - 60.37 Perf YTD0.04%
Dividend Est.- P/FCF- EPS past 5Y-15.75% ROI-46.58% 52W High-20.76% Beta0.56
Dividend TTM- Quick Ratio2.65 Sales past 5Y63.06% Gross Margin81.19% 52W Low40.46% ATR (14)1.95
Dividend Ex-Date- Current Ratio2.81 EPS Y/Y TTM28.02% Oper. Margin-102.49% RSI (14)27.20 Volatility5.08% 3.49%
Employees1276 Debt/Eq2.63 Sales Y/Y TTM27.44% Profit Margin-106.93% Recom1.19 Target Price92.57
Option/ShortYes / Yes LT Debt/Eq2.46 EPS Q/Q37.24% Payout- Rel Volume1.22 Prev Close50.73
Sales Surprise3.11% EPS Surprise5.65% Sales Q/Q42.27% EarningsNov 05 AMC Avg Volume707.27K Price47.84
SMA20-9.40% SMA50-12.68% SMA200-0.46% Trades Volume856,956 Change-5.70%
Date Action Analyst Rating Change Price Target Change
Jun-06-24Upgrade Goldman Neutral → Buy $56 → $67
Apr-22-24Initiated RBC Capital Mkts Outperform $77
Dec-08-23Initiated Wells Fargo Overweight $72
Jun-14-23Resumed Credit Suisse Outperform $96
Jun-06-23Upgrade Evercore ISI In-line → Outperform $60 → $80
Apr-26-23Initiated Cantor Fitzgerald Overweight $114
Jan-18-23Resumed Canaccord Genuity Buy $90
Dec-30-22Resumed H.C. Wainwright Buy $82
Nov-03-22Upgrade Robert W. Baird Neutral → Outperform $50
Oct-13-22Upgrade Guggenheim Neutral → Buy $50
Nov-09-24 10:30AM
Nov-06-24 02:27AM
Nov-05-24 04:11PM
04:01PM
Nov-01-24 09:16AM
04:05PM Loading…
Oct-29-24 04:05PM
Oct-18-24 04:30PM
Oct-07-24 08:00AM
Oct-03-24 04:30PM
Sep-26-24 08:00AM
Sep-18-24 05:00PM
Sep-05-24 01:07AM
Sep-02-24 06:05PM
Aug-29-24 04:30PM
Aug-21-24 04:30PM
10:45AM Loading…
Aug-06-24 10:45AM
Aug-02-24 08:15AM
07:44AM
Aug-01-24 04:17PM
04:05PM
Jul-25-24 04:05PM
Jul-24-24 08:00AM
Jul-22-24 04:27PM
Jul-19-24 04:05PM
Jul-18-24 09:03AM
Jul-17-24 04:05PM
Jun-20-24 04:30PM
Jun-17-24 03:27PM
Jun-13-24 08:49PM
10:15AM
05:12AM Loading…
05:12AM
03:14AM
Jun-12-24 04:05PM
04:00PM
10:46AM
07:45AM
Jun-11-24 05:47PM
Jun-04-24 04:05PM
May-31-24 10:36AM
May-30-24 04:00PM
May-22-24 02:27PM
May-17-24 04:30PM
May-07-24 04:30PM
May-04-24 10:24AM
May-03-24 03:01PM
12:22PM
May-02-24 08:58PM
08:00PM
05:49PM
05:10PM
04:08PM
04:00PM
Apr-30-24 04:00PM
08:00AM
Apr-25-24 04:30PM
Apr-19-24 04:30PM
Apr-16-24 11:33AM
Apr-15-24 07:30AM
07:00AM
Apr-12-24 04:22PM
08:00AM
Mar-22-24 04:00PM
Mar-20-24 08:11AM
Mar-12-24 05:00PM
Mar-11-24 03:00PM
Mar-08-24 09:38AM
Feb-27-24 04:30PM
Feb-23-24 04:05PM
Feb-16-24 10:43AM
10:35AM
07:53AM
Feb-15-24 04:15PM
04:01PM
Feb-13-24 01:36PM
Feb-08-24 04:00PM
Feb-06-24 08:00AM
Feb-05-24 04:05PM
Jan-25-24 04:05PM
Jan-19-24 04:00PM
Jan-18-24 02:41PM
Jan-09-24 06:20PM
Jan-08-24 12:18PM
07:00AM
Jan-07-24 11:00AM
Jan-04-24 08:12AM
08:00AM
Jan-03-24 08:00AM
Jan-02-24 04:05PM
Dec-27-23 06:41PM
Dec-21-23 05:21PM
04:30PM
Dec-18-23 09:29AM
08:00AM
Dec-15-23 10:18AM
Nov-20-23 04:30PM
Nov-17-23 04:30PM
Nov-07-23 05:00PM
Nov-04-23 01:12PM
12:16PM
Nov-03-23 11:43AM
Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Horn HowardChief Financial OfficerOct 10 '24Sale52.767,465393,85392,301Oct 11 04:48 PM
KAKKIS EMIL DPresident & CEOSep 03 '24Sale55.8520,0001,117,0002,223,985Sep 05 11:53 AM
Huizenga Theodore AlanSVP, Chief Accounting OfficerSep 03 '24Sale56.19915,11341,551Sep 05 11:50 AM
KAKKIS EMIL DOfficerSep 03 '24Proposed Sale55.8520,0001,117,096Sep 03 04:40 PM
KAKKIS EMIL DPresident & CEOAug 06 '24Sale50.1720,0001,003,4002,243,985Aug 07 02:48 PM
KAKKIS EMIL DOfficerAug 06 '24Proposed Sale50.1720,0001,003,418Aug 06 04:28 PM
Sanders Corazon (Corsee) D.DirectorJul 02 '24Sale40.9858423,93212,009Jul 03 02:07 PM
Parschauer Karah HerdmanEVP and Chief Legal OfficerJun 12 '24Sale45.009,806441,27057,981Jun 12 07:47 PM
Sanders Corazon (Corsee) D.DirectorJun 10 '24Sale41.101,73771,3917,248Jun 10 07:58 PM
Crombez EricEVP and Chief Medical OfficerMay 02 '24Sale43.6635415,45648,431May 03 03:23 PM
Crombez EricEVP and Chief Medical OfficerApr 18 '24Sale44.101426,26248,785Apr 19 04:35 PM
Kassberg Thomas RichardCBO & EVPMar 11 '24Sale49.9311,509574,644252,823Mar 12 01:41 PM
Fust Matthew KDirectorMar 07 '24Sale50.8812,195620,44314,860Mar 11 12:54 PM
Parschauer Karah HerdmanEVP and Chief Legal OfficerMar 01 '24Sale53.763,756201,92367,340Mar 05 08:22 PM
Kassberg Thomas RichardCBO & EVPMar 01 '24Sale53.761,01154,351264,332Mar 05 08:19 PM
Pinion John RichardSee RemarksMar 01 '24Sale53.764,173224,34089,268Mar 05 08:15 PM
Huizenga Theodore AlanSVP, Chief Accounting OfficerMar 01 '24Sale53.7634118,33241,380Mar 05 08:13 PM
Crombez EricEVP and Chief Medical OfficerMar 01 '24Sale53.761,23866,55548,927Mar 05 08:10 PM
Harris ErikEVP & Chief Commercial OfficerMar 01 '24Sale53.764,768256,32867,163Mar 05 08:08 PM
KAKKIS EMIL DPresident & CEOFeb 07 '24Sale45.0030,0001,350,000539,770Feb 08 03:49 PM
KAKKIS EMIL DPresident & CEODec 29 '23Sale47.8730,0001,436,100569,770Jan 02 04:07 PM
Huizenga Theodore AlanSVP, Chief Accounting OfficerJan 02 '24Option Exercise21.003,00063,00027,892Jan 02 04:06 PM